Zai Lab Doses First Patient in China Trial of PD-1 for NSCLC
October 08, 2020 at 05:09 AM EDT
Zai Lab of Shanghai has dosed the first patient in a China Phase III trial of retifanlimab, an anti-PD-1 antibody, as a first line treatment for metastatic non-small-cell-lung cancer (NSCLC). In 2019, Zai in-licensed China rights to the candidate from Incyte in a $77.5 million agreement. Zai will be in charge of the China arm of Incyte's global Phase III trial of retifanlimab, which will be administered in combination with platinum-based chemotherapy. More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //